Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Woodstock Corp

Woodstock Corp grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,222 shares of the biopharmaceutical company’s stock after purchasing an additional 170 shares during the period. Woodstock Corp’s holdings in Regeneron Pharmaceuticals were worth $4,064,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also modified their holdings of the company. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $932,571,000. International Assets Investment Management LLC grew its holdings in Regeneron Pharmaceuticals by 76,169.5% during the 4th quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock worth $519,148,000 after acquiring an additional 590,314 shares in the last quarter. First Trust Advisors LP grew its stake in shares of Regeneron Pharmaceuticals by 115.2% during the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after purchasing an additional 195,902 shares in the last quarter. abrdn plc increased its holdings in shares of Regeneron Pharmaceuticals by 552.8% in the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after acquiring an additional 186,215 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Regeneron Pharmaceuticals by 129.3% during the 4th quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company’s stock worth $190,170,000 after buying an additional 122,103 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

REGN has been the topic of several research analyst reports. Evercore ISI started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target on the stock. TD Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Bank of America raised their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Cantor Fitzgerald restated a “neutral” rating and set a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, May 3rd. Finally, JPMorgan Chase & Co. raised their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research note on Monday. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $998.09.

Insiders Place Their Bets

In related news, Director Michael S. Brown sold 1,172 shares of the stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the sale, the director now owns 1,382 shares in the company, valued at $1,347,256.52. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,535 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $1,040.00, for a total value of $1,596,400.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at $1,437,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. Insiders sold a total of 61,215 shares of company stock valued at $60,414,782 over the last 90 days. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Up 0.1 %

Regeneron Pharmaceuticals stock traded up $1.42 during midday trading on Thursday, hitting $1,040.53. 138,203 shares of the stock were exchanged, compared to its average volume of 465,870. Regeneron Pharmaceuticals, Inc. has a 1 year low of $684.80 and a 1 year high of $1,052.34. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The firm has a market cap of $114.66 billion, a P/E ratio of 30.70, a P/E/G ratio of 2.15 and a beta of 0.13. The company has a 50 day moving average price of $962.39 and a two-hundred day moving average price of $940.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The company had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.